Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

Wedbush analyst Robert Driscoll has downgraded Foghorn Therapeutics (NASDAQ: FHTX) from an Outperform rating to Neutral. Additionally, the price target for the stock has been significantly reduced from $10 to $2.